MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

GSK547

CAS No. : 2226735-55-1

MCE 站：GSK547

产品活性：GSK547 (GSK'547) 是一种高效的选择性 receptor-interacting serine/threonine protein kinase 1 (RIPK1) 抑制剂，可抑制巨噬细胞介导的胰腺癌适应性免疫耐受。

研究领域：Apoptosis

作用靶点：RIP kinase

In Vitro: GSK547 (0.1-100000 nM; 24 hours) pretreats L929 cells with recombinant TNFα and zVAD at various doses for 30 min, then cell death is induced with an IC₅₀ of 32 nM after 24 hours.
GSK547 up-regulates STAT1 signaling in bone marrow-derived macrophages (BMDM).

In Vivo: GSK547 (GSK′547; RIP1i) robustly targets RIP1 in vivo. RIP1 inhibition results in immunogenic macrophage differentiation in pancreatic cancer, leading to adaptive immune activation and tumor protection for pancreatic ductal adenocarcinoma (PDA).
GSK547 (100 mg/kg/day; fed via food-based dosing; 15-50 days) reduces tumor burden and extends survival compared with mice treated with controls or Nec-1s.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Kinase Inhibitor Library  |  NF-κB Signaling Compound Library  |  Anti-Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Necrostatin-1  |  GSK-872  |  GSK583  |  GSK840  |  GSK-843  |  HS-1371  |  RIP2 kinase inhibitor 2  |  PROTAC RIPK degrader-2  |  RIPK-IN-4  |  RIPK1-IN-4  |  RIPK1-IN-7  |  PROTAC RIPK degrader-6  |  Kongensin A  |  GNE684  |  cRIPGBM

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。